General contact

Main switchboard

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 a.m. - 5:00 p.m. GMT+1

US switchboard

+1 862 778 21 00
Monday - Friday,
8:30 a.m. - 5:00 p.m. EST


Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999


Investor Relations

Monday - Friday,
8:30 a.m. - 5:30 p.m. GMT+1
(Central European Time)

Reporting side effects

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

Reporting side effects

pane 4 content

Clinical trial information disclosure

Research based companies are required to prove safety and efficacy of all new medicines in clinical trials. Clinical studies in humans must comply with ethical principles, as agreed in the Declaration of Helsinki, that protect the safety and well-being of the study participants.

Providing access to information about clinical research studies and their results benefits study participants, patients, healthcare providers and the wider public. This information helps people make informed decisions about potential participation in clinical studies.

Clinical trial information disclosure at Novartis

Novartis is committed to timely disclosure of the design and results of all interventional clinical studies for innovative treatments. Results are to be made publicly available whatever their outcome.

Novartis makes all efforts to comply with national and international standards for disclosure of clinical trial information in a timely manner. Clinical studies are designed and conducted in accordance with the ethical principles of the Declaration of Helsinki Good Clinical Practice guidelines as well as national and international regulatory requirements.

To learn more about how Novartis is leading in clinical trial data transparency: